Long-Term Management of Gout Nonpharmacologic and Pharmacologic Therapies

被引:16
作者
Chaichian, Yashaar [1 ]
Chohan, Saima [1 ]
Becker, Michael A. [1 ]
机构
[1] Univ Chicago, Rheumatol Sect, Chicago, IL 60637 USA
关键词
Gout; Hyperuricemia; Risk reduction; Urate-lowering therapy; Allopurinol; Febuxostat; Uricosuric agents; Pegloticase; URIC-ACID LEVEL; NUTRITION EXAMINATION SURVEY; URATE-LOWERING THERAPY; 3RD NATIONAL-HEALTH; SERUM URATE; RISK-FACTORS; ANTIHYPERURICEMIC THERAPY; INCIDENT GOUT; HYPERSENSITIVITY SYNDROME; CONVENTIONAL TREATMENT;
D O I
10.1016/j.rdc.2014.01.012
中图分类号
R5 [内科学];
学科分类号
100201 [内科学];
摘要
Gout is a common disorder with clinical signs and symptoms resulting from inflammatory responses to monosodium urate crystals deposited in tissues from extracellular fluids saturated for urate. Long-term management of gout focuses on nonpharmacologic and pharmacologic means to achieve and maintain serum urate levels in a subsaturating range. Despite a firm understanding of gout pathophysiology, means to achieve certain diagnosis, and a variety of effective therapies, treatment outcomes remain suboptimal. In this review, available nonpharmacologic and pharmacologic therapies for chronic gout are discussed and a framework is provided for successful achievement and maintenance of goal-range serum urate levels.
引用
收藏
页码:357 / +
页数:19
相关论文
共 91 条
[1]
New-onset gout after kidney transplantation: Incidence, risk factors and implications [J].
Abbott, KC ;
Kimmel, PL ;
Dharnidharka, V ;
Oglesby, RJ ;
Agodoa, LY ;
Caillard, S .
TRANSPLANTATION, 2005, 80 (10) :1383-1391
[2]
Plasma urate level is directly regulated by a voltage-driven urate efflux transporter URATv1 (SLC2A9) in humans [J].
Anzai, Naohiko ;
Ichida, Kimiyoshi ;
Jutabha, Promsuk ;
Kimura, Toru ;
Babu, Ellappan ;
Jin, Chun Ji ;
Srivastava, Sunena ;
Kitamura, Kenichiro ;
Hisatome, Ichiro ;
Endou, Hitoshi ;
Sakurai, Hiroyuki .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2008, 283 (40) :26834-26838
[3]
ALLOPURINOL HYPERSENSITIVITY SYNDROME - A REVIEW [J].
ARELLANO, F ;
SACRISTAN, JA .
ANNALS OF PHARMACOTHERAPY, 1993, 27 (03) :337-343
[4]
Arromdee E, 2002, J RHEUMATOL, V29, P2403
[5]
Febuxostat compared with allopurinol in patients with hyperuricemia and gout [J].
Becker, MA ;
Schumacher, HR ;
Wortmann, RL ;
MacDonald, PA ;
Eustace, D ;
Palo, WA ;
Streit, J ;
Joseph-Ridge, N .
NEW ENGLAND JOURNAL OF MEDICINE, 2005, 353 (23) :2450-2461
[6]
Becker MA., 2014, UpToDate
[7]
Long-term safety of pegloticase in chronic gout refractory to conventional treatment [J].
Becker, Michael A. ;
Baraf, Herbert S. B. ;
Yood, Robert A. ;
Dillon, Aileen ;
Vazquez-Mellado, Janitzia ;
Ottery, Faith D. ;
Khanna, Dinesh ;
Sundy, John S. .
ANNALS OF THE RHEUMATIC DISEASES, 2013, 72 (09) :1469-1474
[8]
The urate-lowering efficacy and safety of febuxostat in the treatment of the hyperuricemia of gout: the CONFIRMS trial [J].
Becker, Michael A. ;
Schumacher, H. Ralph ;
Espinoza, Luis R. ;
Wells, Alvin F. ;
MacDonald, Patricia ;
Lloyd, Eric ;
Lademacher, Christopher .
ARTHRITIS RESEARCH & THERAPY, 2010, 12 (02)
[9]
Clinical Efficacy and Safety of Successful Longterm Urate Lowering with Febuxostat or Allopurinol in Subjects with Gout [J].
Becker, Michael A. ;
Schumacher, H. Ralph ;
MacDonald, Patricia A. ;
Lloyd, Eric ;
Lademacher, Christopher .
JOURNAL OF RHEUMATOLOGY, 2009, 36 (06) :1273-1282
[10]
Epidemiology of Gout in Women Fifty-two-Year Followup of a Prospective Cohort [J].
Bhole, Vidula ;
de Vera, Mary ;
Rahman, M. Mushfiqur ;
Krishnan, Eswar ;
Choi, Hyon .
ARTHRITIS AND RHEUMATISM, 2010, 62 (04) :1069-1076